BJU Int
- LEWICKI P, Ginsburg K, Mmonu N, Labardee C, et al
What is lost in an average? Identifying distinct post-radical prostatectomy
functional recovery profiles.
BJU Int. 2025;136:633-639.
- ZAURITO P, Westerberg M, Garmo H, Gedeborg R, et al
Urinary tract events after radical radiotherapy (RT) for prostate cancer
according to pre-RT International Prostate Symptom Score.
BJU Int. 2025 Sep 12. doi: 10.1111/bju.16927.
- BYRNE MHV, Anbarasan T, Browning L, Woodcock DJ, et al
What spatial omics is teaching us about field cancerisation in prostate and
bladder cancer.
BJU Int. 2025 Jun 25. doi: 10.1111/bju.16830.
- HALL R, Ball R, Bancroft E, Eeles R, et al
Systematic review of PSA reference intervals in the gender diverse population
with prostates.
BJU Int. 2025;136:568-577.
- VISSCHER J, Bonevski B, O'Callaghan M
The association of smoking with urinary and sexual function recovery following
radical prostatectomy.
BJU Int. 2025;136:647-656.
BMC Urol
- INOUE K, Shinohara M, Saka T, Hirao Y, et al
Correction: Evaluation of the changes in hydrogel spacer volume in patients
treated with proton therapy for prostate cancer.
BMC Urol. 2025;25:228.
Clin Cancer Res
- BLINKA S, Yu EY
Drug targets in prostate cancer: an appetite for KLK2-mediated destruction.
Clin Cancer Res. 2025 Sep 9. doi: 10.1158/1078-0432.CCR-25-2546.
Eur Radiol
- GIROMETTI R, Peruzzi V, Clauser P, Potsch N, et al
Diffusion levels for quantitative assessment of the apparent diffusion
coefficient value in prostate MRI: a proof-of-concept bicentric study.
Eur Radiol. 2025;35:6171-6182.
Eur Urol
- LI S, Wang C
Re: Sarah Burdett, David J Fisher, Jayne F. Tierney, et al. Duration of Androgen
Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate
Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data.
Eur Urol.
Eur Urol. 2025 Sep 6:S0302-2838(25)00480-4. doi: 10.1016/j.eururo.2025.
- LI J, Zhang Y, Hu H
Re: Metformin for Patients with Metastatic Prostate Cancer Starting Androgen
Deprivation Therapy: A Randomised Phase 3 Trial of the STAMPEDE Platform
Protocol.
Eur Urol. 2025 Sep 8:S0302-2838(25)00483-X. doi: 10.1016/j.eururo.2025.
- DU Y, Liu D, Guan Z
Re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance
Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results
from a Large Cohort Study. Eur Urol. In press.
https://doi.org/10.1016/j.eururo.2025.03.0
Eur Urol. 2025 Sep 9:S0302-2838(25)00478-6. doi: 10.1016/j.eururo.2025.
Int J Cancer
- LIN E, Garmo H, Beckmann K, Bratt O, et al
Prostate cancer characteristics in fathers and risk of early onset high-risk
prostate cancer in sons.
Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70133.
Int J Radiat Oncol Biol Phys
- TISSEVERASINGHE S, Niazi T
Pelvic Nodal Irradiation Should Be Offered to High-Risk Prostate Cancer Patients
Receiving Radiation Therapy.
Int J Radiat Oncol Biol Phys. 2025;123:387-391.
- ACHARD V, Benziane-Ouaritini N, Sargos P
Hypofractionated Radiation Therapy for Prostate Cancer in the Postoperative
Setting: Is It Capable of Going the Distance?
Int J Radiat Oncol Biol Phys. 2025;123:381-383.
- RAMADAN S, Loblaw A, Dhar A, Fakir H, et al
PSMA MRI Guided prOstate SBRT (ARGOS)/Comprehensive, Longitudinal Evaluation of
IMaging BiomarkErs Post Radiotherapy (CLIMBER) Phase I/II Trial.
Int J Radiat Oncol Biol Phys. 2025;123:395-405.
- RANTA K, Wojcieszynski AP, Zhao SG, Liu Y, et al
Severe Late Toxicities (Grade 3-5) With 13 Years of Follow-up after
Hypofractionated Postprostatectomy Radiotherapy.
Int J Radiat Oncol Biol Phys. 2025;123:374-380.
- SAAD E, Hoskin P, Choudhury A
Prophylactic Pelvic Nodal Radiation Therapy in High-risk Node-negative Prostate
Cancer: The Case Against.
Int J Radiat Oncol Biol Phys. 2025;123:392-394.
J Nucl Med
- BEINTNER-SKAWRAN S, Gafita A, Lorenzini T, Tauber R, et al
[(68)Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with
Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy.
J Nucl Med. 2025 Sep 11:jnumed.125.269584. doi: 10.2967/jnumed.125.269584.
J Urol
- DASKIVICH TJ, Stock SR, Cummings S, Masterson JM, et al
Risks of Progression After Early Androgen Deprivation Therapy for Biochemical
Recurrence After Radical Prostatectomy.
J Urol. 2025;214:354-364.
- FREITAS PFS, Khandekar A, Porto JG, Yu H, et al
Can Genomic Classifiers in Biopsy Cores With Grade Group 1 Cancer Predict
Higher-Grade Disease Elsewhere in the Prostate? Results From the Prospective
Miami Active Surveillance Trial.
J Urol. 2025;214:383-392.
JAMA
- NG ABCD, Asif A, Agarwal R, Panebianco V, et al
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME
Diagnostic Clinical Trial.
JAMA. 2025 Sep 10:e2513722. doi: 10.1001/jama.2025.13722.
PLoS One
- BACH CA, Hossain MN, Chaudhari IJ, Verrillo CE, et al
A novel sialylation pathway mediated by extracellular vesicles in aggressive
prostate cancer.
PLoS One. 2025;20:e0329014.
Prostate
- HUNT TC, Malshy K, Steidle M, Li A, et al
Impact of Testosterone Recovery on Oncologic Outcomes in High-Risk, Localized
Prostate Cancer.
Prostate. 2025 Sep 9. doi: 10.1002/pros.70043.
- FALKENBACH F, Di Bello F, Penaranda NR, Longoni M, et al
USPSTF Recommendation Against PSA Screening vs. Stage and Cancer-Specific
Mortality in Localized Prostate Cancer.
Prostate. 2025 Sep 9. doi: 10.1002/pros.70045.
Radiol Artif Intell
- MORADI A, Zerka F, Bosma JS, Sunoqrot MRS, et al
Optimizing Federated Learning Configurations for MRI Prostate Segmentation and
Cancer Detection: A Simulation Study.
Radiol Artif Intell. 2025 Jul 30:e240485. doi: 10.1148/ryai.240485.
Urology
- MARTIN C, Maoate K, Hooshyari A, Ordones FV, et al
Transitioning to Office-based Transperineal Prostate Biopsy-A Case Study From a
Regional New Zealand Hospital in Economic and Environmental Sustainability.
Urology. 2025;203:53-59.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016